GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Net Income From Continuing Operations

Oncodesign Precision Medicine (XPAR:ALOPM) Net Income From Continuing Operations : €-3.26 Mil (TTM As of Jun. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Oncodesign Precision Medicine's net income from continuing operations for the six months ended in Jun. 2022 was €-3.26 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2022 was €-3.26 Mil.

Oncodesign Precision Medicine Net Income From Continuing Operations Historical Data

The historical data trend for Oncodesign Precision Medicine's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Net Income From Continuing Operations Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
Net Income From Continuing Operations
-4.71 -2.94

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
Net Income From Continuing Operations - - -3.26

Oncodesign Precision Medicine Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Net Income From Continuing Operations
Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines